Dysphagia Associated Organ Sparing Radiotherapy: Defining the Limits of Tolerance for Late Toxicity

Bindhu Joseph


Background: Dysphagia after radiotherapy in head and neck malignancies can severely impact a patient’s physical, social and psychological quality of life. Aspiration remains the major cause of non-disease related mortality in treated patients. The purpose of this study was to analyze the dosimetric correlates in a selective Asian subset of patients who are most eligible for Dysphagia aspiration related structure (DARS) sparing. Materials and Methods: Thirty patients with Oral or Oropharyngeal malignancies treated from March 2014 to September 2017 were analyzed for dosimetric parameters to DARS. A dosimetric and volumetric evaluation of dose parameters to the dysphagia and Aspiration associated normal structures were analyzed. The National cancer institute Common toxicity criteria for adverse events Version- 3 was used to grade late dysphagia. Subjective evaluation of dysphagia was done with University of Washington Head and Neck related quality of life Questionnaire. Dosimetric comparison between IMRT and 3DCRT technique was done and correlated to toxicity. Results: Greater than Grade 2 dysphagia was observed in 10 patients (33%). In the 3DCRT cohort Grade 3 & 4 toxicity was higher, 50 % vs 25 %. A threshold Mean dose of 63 Gy was identified as a significant parameter above which observed Gr 3/4 toxicity was 33% (p value=0.028). The maximum dose to the base of tongue (BOT) and Superior constrictor (SC) were dosimetric parameters which achieved significance (p value=0.013 & 0.005). There was no difference in the dose delivered to DARS between 3DCRT and IMRT. However, the patient reported Dysphagia scores were higher for pain (p=0.0014) in the 3DCRT cohort and can be attributed to a higher percentage of patients exceeding Parotid tolerance (70% vs 40%). The impact of Gr 3/4 toxicity on all aspects of quality of life parameters were significantly impaired with maximum compromise on late chewing, swallowing and general perception of well-being (p value =0.001). Conclusion: This suggests that a threshold mean dose (MD) of 63 Gy to the constrictors is statistically correlated to significant Gr 3/4 late toxicity. The high doses to the BOT and SC independently contribute to late toxicity. IMRT is more efficient in reducing severe late toxicity with a better patient reported quality of life parameters and should be the preferred treatment of choice.


IMRT; head and neck cancers; dysphagia and aspiration associated structures; late dysphagia

Full Text:



Langendijk JA, Doornaert P, Verdonck-de Leeuw, Leemans CR, Aaronson NK, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008;26:3770-6.

Goguen LA, Posner MR, Norris CM, et al. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. OtolaryngolHead Neck Surg 2006;134:916-22.

List MA, Siston A, Haraf D, et al. Quality of life and performance in advancedhead and neck cancer patients on concomitant chemoradiotherapy: aprospective examination. J Clin Oncol 1999;17:10208.

Nguyen NP, Frank C, Moltz CC, et al. Impact of dysphagia on quality of life after treatment of head-and-neck cancer.Int J Radiat Oncol Biol Phys 2005;61:772-8.

Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol 2007;85:74-82.

Smith RV, Kotz T, Beitler JJ, Wadler S. Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results. Arch Otolaryngol Head Neck Surg 2000;126:384-9.

Wu CH, Hsiao TY, Ko JY, Hsu MM. Dysphagia after radiotherapy: endoscopic examination of swallowing in patients with nasopharyngeal carcinoma. Ann OtolRhinolLaryngol 2000;109:320-5.

Nguyen NP, Moltz CC, Frank C, et al. Dysphagia severity following chemoradiation and postoperative radiation for head and neck cancer. Eur J Radiol 2006;59:453-9.

Senkal HA, Hayran M, Karakaya E, Yueh B, Weymuller EA Jr, Hosal AS. The validity and reliability of the Turkish version of the University of Washington quality of life questionnaire for patients with head and neck cancer. Am J Otolaryngol 2012;33:417-26.

Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S.Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2009;75:385-92.

Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:1110-8.

Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004;60:1425-39.

Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007;68:1289-98.

Fua TF, Corry J, Milner AD, Cramb J, Walsham SF, Peters LJ. Intensity- modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo-esophageal axis and dysphagia. Int J Radiat Oncol Biol Phys 2007;67:976-81.

Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship.Radiother Oncol 2007;85:6473.

Li B, Li D, Lau DH, et al. Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy. Radiat Oncol 2009;4:52.

Bhide SA, Gulliford S, Kazi R, et al. Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo- IMRT for head and neck cancer. Radiother Oncol 2009;93:539-44.

Caudell JJ, Schaner PE, Desmond RA, Meredith RF,Spencer SA, Bonner JA. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010;76:403-9.

Petkar I, Rooney K, Roe JW, et al. DARS: a phase III randomized multicentre study of dysphagia- optimised intensity- modulated adiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer. BMC Cancer 2016;16(1):770.

Nutting CM, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicenter randomized controlled trial. Lancet Oncol 2011;12(2):127-36.

DOI: http://dx.doi.org/10.30564/amor.v4i5.189


  • There are currently no refbacks.

Copyright (c) 2019 Bindhu Joseph

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.